Figure 5.
Nicotinamide mononucleotide (NMN) improves the health of CSMN that become diseased due to TDP-43 pathology. (a) a representative image of CSMN from prpTDP-43A315T-UeGFP mouse; (b) a representative image of CSMN from prpTDP-43A315T-UeGFP mouse treated with 1 µM NMN; (c) a representative image of CSMN from WT-UeGFP mouse; (d) a representative image of CSMN from WT-UeGFP mouse treated with NMN. (e) Bar graph representation of average neurite length; (f) Percent distribution of axon length; and (g) Sholl analysis of arborization of neurites. Scale bar = 20 µm.